Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

WuXi Biologics Opens Expanded $150 Million Biomanufacturing Facility

publication date: Dec 7, 2017

WuXi Biologics has completed construction of its $150 million 30,000 liter biomanufacturing facility in China. The CRO/CMO initially announced it would build the facility in April 2015. Completed in two stages, the plant has begun operating fourteen 2,000 liter disposable bioreactors for fed-batch cell culture in the facility, the second construction phase, greatly expanding Phase I capacity, which consisted of two 1000 liter disposable bioreactors. WuXi Biologics' plant, located in Wuxi city offers cGMP contract manufacturing services for biologic drugs to WuXi clients. More details....

Stock Symbol: (HK: 2269)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.